Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 7/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627733 | 1.00 | SCN8A (0.44) | SCN8ATRPM8SCN1ASCN5ARORC | |
| SCHEMBL20252642 | 0.89 | SCN8A (0.43) | SCN8ASCN1ASCN5A | |
| SCHEMBL22590213 | 0.87 | SCN8A (0.42) | SCN8ASCN1ASCN5ALMNA | |
| SCHEMBL19627627 | 0.87 | SCN8A (0.46) | SCN8ASCN1ASCN5ARORCTP53 | |
| SCHEMBL19614057 | 0.86 | TRPM8 (0.42) | SCN8ATRPM8SCN1ASCN5AERAP1 | |
| SCHEMBL30045900 | 0.84 | SCN8A (0.43) | SCN8ATRPM8SCN1ASCN5A | |
| SCHEMBL21783535 | 0.84 | SCN8A (0.43) | SCN8ATRPM8SCN1ASCN5A | |
| SCHEMBL1094339 | 0.84 | SCN8A (0.43) | SCN8ASCN1ASCN5ARORC | |
| SCHEMBL23456672 | 0.83 | SCN8A (0.62) | SCN8ASCN1ASCN5A | |
| SCHEMBL20252643 | 0.83 | SCN8A (0.62) | SCN8ASCN1ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SCN8A 14/4885TRPM8 43/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.